Nature's Sunshine Products Inc

Nature's Sunshine Products Inc(NATR)の株式分析

$12.840

+0.819 (+6.38%)終値時点

Loading chart…
高値
12.940
始値
12.340
出来高加重平均価格
12.70
出来高
123.14K
時価総額
281.51M
安値
12.320
売買代金
1.56M
EV/EBITDA(TTM)
3.91

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk.

AI分析 of Nature's Sunshine Products Inc (NATR)

中立

Nature's Sunshine Products Inc (NATR) is currently trading at $12.02, significantly below its 52-week high of $28.14, indicating potential for recovery. However, the stock has a low RSI of 28.072, suggesting it is oversold, but the recent earnings miss and lowered guidance raise concerns about future performance. The forward P/E ratio is 8.87, which is attractive, but the net income has been inconsistent, with a recent drop to $3.54 million in Q2 2026. The main risk is the insider selling, which has increased by 161.97% over the last month, indicating lack of confidence among insiders. Therefore, while there is potential for upside, the current market sentiment and risks suggest holding rather than buying at this time.

バリュエーション指標

Nature's Sunshine Products Inc(NATR)の現在の予想PERは8.71で、5年平均は12.41です。

予想PER

適正
5年平均 P/E
12.41
現在のP/E
8.71
割高
57.86
割安
-33.04

予想EV/EBITDA

適正
5年平均 EV/EBITDA
6.44
現在のEV/EBITDA
3.91
割高
9.12
割安
3.77

予想PSR

割安
5年平均 P/S
0.62
現在のP/S
0.41
割高
0.76
割安
0.48

Alphio AI による NATR の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%NATR

$16.58

シナリオ価格

基

基本

基本 · 50%NATR

$16.06

シナリオ価格

弱

弱気

弱気 · 25%NATR

$14.23

シナリオ価格

NATR を保有するクジラ

S

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

+ を保有NATR

-15.12%

3か月リターン

イベントタイムライン

2026-11-04 (ET)

17:30:00

Nature's Sunshine Reports Q3 Revenue of $116.6M

17:30:00

Nature's Sunshine Cuts FY26 Adjusted EBITDA Outlook to $44M-$48M

2026-08-06 (ET)

18:30:00

Nature's Sunshine Appoints Ruth Perkins as CFO

2026-05-07 (ET)

17:50:00

Reiterates FY26 Revenue View of $500M-$515M

17:50:00

Company Reports Q1 Revenue of $122.9M

ニュース

NATR のよくある質問 — Alphio AI が回答

Nature's Sunshine Products, Inc. is a natural health and wellness company, which markets and distributes nutritional and personal care products in more than 40 countries. The Company sells its products to a sales force of independent consultants who use the products themselves or resell them to consumers. The Company has four segments: Asia, Europe, North America, and Latin America and Other. Each of the geographic segments operates under the Natures Sunshine Products and Synergy WorldWide brands. The Latin America and Other segment include its wholesale business, in which the Company sells products to various locally managed entities, independent of the Company, that it has granted distribution rights for the relevant market. The Company's line of over 800 products includes several different product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. It purchases herbs and other raw materials in bulk. It operates in the Consumer Non-Cyclicals sector (PHARMACEUTICAL PREPARATIONS industry).

Nature's Sunshine Products Inc (NATR) is currently trading at $12.02, significantly below its 52-week high of $28.14, indicating potential for recovery. However, the stock has a low RSI of 28.072, suggesting it is oversold, but the recent earnings miss and lowered guidance raise concerns about future performance. The forward P/E ratio is 8.87, which is attractive, but the net income has been inconsistent, with a recent drop to $3.54 million in Q2 2026. The main risk is the insider selling, which has increased by 161.97% over the last month, indicating lack of confidence among insiders. Therefore, while there is potential for upside, the current market sentiment and risks suggest holding rather than buying at this time.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める